Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central anxious method, conolidine modulates alternate molecular targets. A Science Advances examine discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://cates984ynu4.bcbloggers.com/profile